casserole of nonsense
Well-Known Member
The EMA, not the FDA, is responsible for regulating the approval and monitoring of drugs for use in humans in EU. Not all FDA-approved products are EMA-approved, and vice versa. UK is still a member of the EMA post-Brexit, but that transition agreement currently runs only until end of 2020. EMA has already moved its HQ from London to Amsterdam, it's in the charter that it has to be based in the EU.Fair questions. I guess we might add to those with do drugs and medicines that currently meet fda standards via EU regulations need to be reevaluated and approved once they are no longer under the EU umbrella and if so what are the costs and timescales of those processes?
Nothing is decided about what happens 1st January 2021 as yet, it's still under negotiation. I hope that UK can remain a full contributor to the EMA, but I understand that drug companies in the UK are also preparing to submit regulatory packages to the MHRA in UK for local approval. This would be a shame, as EMA pools data from all member countries and this is very valuable information.
I couldn't guess at the costs to the UK industry, but it is taking up a large slice of corporate regulatory and safety resource preparing for the MHRA scenario. Re. timescales, drug companies want an unbroken transition (as do patients!) so are mostly already prepared for MHRA submission.
I wouldn't imagine the MHRA would have many, if any, problems with existing EMA status for any drug, having been a significant contributor to EMA processes in the past. It's pretty important that the MHRA continues to be very closely aligned with the EMA, if not a full member.